Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling test

The liquid CGP was useful for detecting FGFR2 fusion and the patient experienced typical side effects (nail disorders, hyperphosphatemia, and taste disorders) of pemigatinib that required treatment.

Detalles Bibliográficos
Autores principales: Ishido, Shun, Tamaki, Nobuharu, Inada, Kento, Itakura, Jun, Takahashi, Yuka, Uchihara, Naoki, Suzuki, Keito, Tanaka, Yuki, Miyamoto, Haruka, Yamada, Michiko, Matsumoto, Hiroaki, Nobusawa, Tsubasa, Keitoku, Taisei, Takaura, Kenta, Tanaka, Shohei, Maeyashiki, Chiaki, Yasui, Yutaka, Tsuchiya, Kaoru, Nakanishi, Hiroyuki, Kurosaki, Masayuki, Izumi, Namiki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320371/
https://www.ncbi.nlm.nih.gov/pubmed/37415592
http://dx.doi.org/10.1002/ccr3.7664

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320371/
https://www.ncbi.nlm.nih.gov/pubmed/37415592
http://dx.doi.org/10.1002/ccr3.7664

Ejemplares similares